Compare Glenmark Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ABBOTT INDIA - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA ABBOTT INDIA GLENMARK PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 13.6 52.4 26.0% View Chart
P/BV x 1.6 15.5 10.1% View Chart
Dividend Yield % 0.6 0.4 145.4%  

Financials

 GLENMARK PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
ABBOTT INDIA
Mar-19
GLENMARK PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs7128,834 8.1%   
Low Rs4845,458 8.9%   
Sales per share (Unadj.) Rs349.61,731.1 20.2%  
Earnings per share (Unadj.) Rs32.8211.9 15.5%  
Cash flow per share (Unadj.) Rs44.3219.9 20.2%  
Dividends per share (Unadj.) Rs2.0065.00 3.1%  
Dividend yield (eoy) %0.30.9 36.8%  
Book value per share (Unadj.) Rs198.6945.2 21.0%  
Shares outstanding (eoy) m282.1721.25 1,327.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.74.1 41.4%   
Avg P/E ratio x18.233.7 54.1%  
P/CF ratio (eoy) x13.532.5 41.5%  
Price / Book Value ratio x3.07.6 39.8%  
Dividend payout %6.130.7 19.9%   
Avg Mkt Cap Rs m168,625151,848 111.0%   
No. of employees `00012.03.5 345.4%   
Total wages/salary Rs m20,5614,356 472.0%   
Avg. sales/employee Rs Th8,196.010,555.5 77.6%   
Avg. wages/employee Rs Th1,708.11,249.9 136.7%   
Avg. net profit/employee Rs Th768.51,292.2 59.5%   
INCOME DATA
Net Sales Rs m98,65536,786 268.2%  
Other income Rs m2,0811,133 183.7%   
Total revenues Rs m100,73637,919 265.7%   
Gross profit Rs m15,8586,047 262.2%  
Depreciation Rs m3,259169 1,926.2%   
Interest Rs m3,34623 14,870.7%   
Profit before tax Rs m11,3356,989 162.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,7562,485 151.2%   
Profit after tax Rs m9,2504,503 205.4%  
Gross profit margin %16.116.4 97.8%  
Effective tax rate %33.135.6 93.2%   
Net profit margin %9.412.2 76.6%  
BALANCE SHEET DATA
Current assets Rs m66,96827,610 242.6%   
Current liabilities Rs m40,2118,569 469.3%   
Net working cap to sales %27.151.8 52.4%  
Current ratio x1.73.2 51.7%  
Inventory Days Days8360 138.4%  
Debtors Days Days8127 296.4%  
Net fixed assets Rs m33,3221,057 3,152.8%   
Share capital Rs m282213 132.8%   
"Free" reserves Rs m55,77019,873 280.6%   
Net worth Rs m56,05220,086 279.1%   
Long term debt Rs m35,7380-   
Total assets Rs m132,88829,409 451.9%  
Interest coverage x4.4311.6 1.4%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.71.3 59.4%   
Return on assets %9.515.4 61.6%  
Return on equity %16.522.4 73.6%  
Return on capital %17.834.9 51.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,998369 17,074.6%   
Fx outflow Rs m22,8594,918 464.8%   
Net fx Rs m40,140-4,549 -882.3%   
CASH FLOW
From Operations Rs m13,2424,991 265.3%  
From Investments Rs m-6,990-2,570 272.0%  
From Financial Activity Rs m-7,387-1,428 517.3%  
Net Cashflow Rs m-2,971993 -299.1%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 6.9 7.9 87.3%  
FIIs % 34.4 0.1 34,400.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.1 61.4%  
Shareholders   56,727 18,270 310.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  CADILA HEALTHCARE  AUROBINDO PHARMA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 202 Points Lower; Oil & Gas and Power Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day on a negative note. At the closing bell, the BSE Sensex stood lower by 202 points.

Related Views on News

ERIS LIFESCIENCES LIMITED Plunges by 8%; BSE HEALTHCARE Index Down 0.9% (Market Updates)

Feb 17, 2020 | Updated on Feb 17, 2020

ERIS LIFESCIENCES LIMITED share price has plunged by 8% and its current market price is Rs 477. The BSE HEALTHCARE is down by 0.9%. The top gainers in the BSE HEALTHCARE Index are SUVEN LIFESCIENCES (up 5.0%) and THYROCARE TECHNOLOGIES (up 2.6%). The top losers are ERIS LIFESCIENCES LIMITED (down 7.5%) and GLENMARK PHARMA (down 6.8%).

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

Buy this 'Crorepati Stock' and You Could End Up Stinking Rich(Profit Hunter)

Feb 5, 2020

I'm talking about an individual small cap stock that could go up so many times that they make their investors stinking rich in the process. You definitely want to know more...

This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years)(Profit Hunter)

Feb 11, 2020

A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.

Will Your Trade Go Up or Down Today?(Fast Profits Daily)

Feb 5, 2020

How you can find out which way your trade is likely to move on any given trading day.

Will Algo Traders Take Away All Your Profits?(Fast Profits Daily)

Feb 11, 2020

How to fight back against algo trading systems.

No Change in My Long-Term View on the Rebirth of India Stocks(The 5 Minute Wrapup)

Feb 6, 2020

Why the recent post budget volatility has not affected my bullish view on the Rebirth of India stocks.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Feb 17, 2020 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS